Translate Bio (TBIO) IPO Opens 12% Lower

Today's IPO for Translate Bio (NASDAQ: TBIO) opened for trading at $11.50 after pricing 9,350,000 shares of its common stock at a price to the public of $13.00 per share.

In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to 1,402,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

Citigroup, Leerink Partners and Evercore ISI are acting as joint book-running managers for the offering.

Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.

You May Also Be Interested In

• SpaceX prices historic IPO at $135/share in largest ever new listing
• SpaceX prices IPO at $135 per share for June 12 Nasdaq debut
• AES prices $1 billion senior notes offering with 2029 and 2033 maturities